MXPA05000128A - Composicion de liberacion controlada. - Google Patents

Composicion de liberacion controlada.

Info

Publication number
MXPA05000128A
MXPA05000128A MXPA05000128A MXPA05000128A MXPA05000128A MX PA05000128 A MXPA05000128 A MX PA05000128A MX PA05000128 A MXPA05000128 A MX PA05000128A MX PA05000128 A MXPA05000128 A MX PA05000128A MX PA05000128 A MXPA05000128 A MX PA05000128A
Authority
MX
Mexico
Prior art keywords
active compound
particles
coated
release
controlled release
Prior art date
Application number
MXPA05000128A
Other languages
English (en)
Inventor
Michael Clark
Original Assignee
Temrel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30117101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05000128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0215656A external-priority patent/GB0215656D0/en
Priority claimed from GB0215657A external-priority patent/GB0215657D0/en
Application filed by Temrel Inc filed Critical Temrel Inc
Publication of MXPA05000128A publication Critical patent/MXPA05000128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una composicion mejorada para controlar el perfil de liberacion de un compuesto activo a traves del tracto intestinal comprende particulas, especialmente pastillas, que contienen el compuesto activo, las cuales son recubiertas con un material de recubrimiento dependiente a disolucion de pH o un material de polimetacrilato, el cual es preferentemente dependiente a disolucion de pH, para un cierto espesor dependiendo de la ubicacion y relacion del compuesto activo que se desea. En composiciones preferidas, dos o mas pluralidades de particulas, en las cuales las particulas de cada pluralidad se recubren con un material de recubrimiento dependiente a disolucion de pH o material de polimetacrilato para un espesor diferente a aquellas de otro pluralidad, estan contenidas dentro de una capsula recubierta entericamente y proporcionan liberacion del compuesto activo en varias ubicaciones deseadas en el tracto intestinal.
MXPA05000128A 2002-07-05 2003-07-04 Composicion de liberacion controlada. MXPA05000128A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215656A GB0215656D0 (en) 2002-07-05 2002-07-05 Controlled release composition
GB0215657A GB0215657D0 (en) 2002-07-05 2002-07-05 Controlled release composition for the treatment of inflammatory bowel disease
PCT/GB2003/002911 WO2004004696A1 (en) 2002-07-05 2003-07-04 Controlled release composition

Publications (1)

Publication Number Publication Date
MXPA05000128A true MXPA05000128A (es) 2005-09-30

Family

ID=30117101

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000128A MXPA05000128A (es) 2002-07-05 2003-07-04 Composicion de liberacion controlada.

Country Status (15)

Country Link
US (4) US20060127484A1 (es)
EP (1) EP1519717B1 (es)
JP (1) JP2005532387A (es)
CN (1) CN1665490A (es)
AT (1) ATE482694T1 (es)
AU (1) AU2003244840C1 (es)
BR (1) BR0312347A (es)
CA (1) CA2491355A1 (es)
DE (1) DE60334378D1 (es)
DK (1) DK1519717T3 (es)
MX (1) MXPA05000128A (es)
NZ (1) NZ537632A (es)
PL (1) PL374922A1 (es)
RU (1) RU2336865C2 (es)
WO (1) WO2004004696A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20070161711A1 (en) 2003-12-23 2007-07-12 Temrel Limited Process for producing pellets for pharmaceutical compositions
US10282785B1 (en) 2004-11-19 2019-05-07 Allstate Insurance Company Delivery of customized insurance products and services
US9875508B1 (en) 2004-11-19 2018-01-23 Allstate Insurance Company Systems and methods for customizing insurance
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PL3095447T3 (pl) 2006-02-03 2022-02-14 Opko Renal, Llc Leczenie niedoboru lub deficytu witaminy d 25-hydroksywitaminą d2 i 25- hydroksywitaminą d3
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
ZA200807111B (en) * 2006-02-09 2009-11-25 Alba Therapeutics Corp Formulations for a tight junction effector
ES2497494T3 (es) 2006-06-21 2014-09-23 Opko Renal, Llc Método de tratamiento y prevención del hiperparatiroidismo secundario
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
JP5444212B2 (ja) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
KR101540369B1 (ko) 2007-04-25 2015-07-29 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
EP3112476B1 (en) 2008-04-02 2023-08-02 EirGen Pharma Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US8465768B2 (en) * 2008-11-07 2013-06-18 Samyang Biopharmaceuticals Corporation Pharmaceutical compositions for release control of methylphenidate
US20100143437A1 (en) * 2008-12-09 2010-06-10 Morris Edward J Implantable analgesic
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
ES2836811T3 (es) * 2010-01-15 2021-06-28 Kemin Ind Zhuhai Co Ltd Alfa-amilasa protegida
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
TW201306881A (zh) * 2011-05-06 2013-02-16 Glaxosmithkline Llc 緩釋對乙醯胺基酚調配物
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
CN110520534A (zh) * 2016-11-09 2019-11-29 恩根尼公司 程序性死亡配体1的肠表达
JP2020502126A (ja) 2016-12-14 2020-01-23 プロジェニティ， インコーポレイテッド 消化管疾病のｊａｋ阻害薬による治療
MX2019006867A (es) * 2016-12-14 2020-01-13 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina.
US20190343425A1 (en) * 2016-12-14 2019-11-14 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
CN113929807B (zh) * 2021-06-25 2022-09-27 贵州省欣紫鸿药用辅料有限公司 一种烯烃酸树脂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
DE19724696A1 (de) * 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
DE60233217D1 (de) * 2001-05-01 2009-09-17 Corium Internat Inc Hydrogel-zusammensetzungen

Also Published As

Publication number Publication date
JP2005532387A (ja) 2005-10-27
DK1519717T3 (da) 2011-01-10
DE60334378D1 (de) 2010-11-11
ATE482694T1 (de) 2010-10-15
RU2005102838A (ru) 2005-08-10
CN1665490A (zh) 2005-09-07
BR0312347A (pt) 2005-04-12
US20140322317A1 (en) 2014-10-30
PL374922A1 (en) 2005-11-14
WO2004004696A1 (en) 2004-01-15
US20110182986A1 (en) 2011-07-28
US20130230588A1 (en) 2013-09-05
AU2003244840A1 (en) 2004-01-23
EP1519717B1 (en) 2010-09-29
RU2336865C2 (ru) 2008-10-27
AU2003244840C1 (en) 2010-03-04
AU2003244840B2 (en) 2009-09-10
NZ537632A (en) 2006-06-30
US20060127484A1 (en) 2006-06-15
EP1519717A1 (en) 2005-04-06
CA2491355A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
MXPA05000128A (es) Composicion de liberacion controlada.
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
AU2003274680A8 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
MY169471A (en) Controlled release preparation
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
MXPA03012041A (es) Sistema de administracion controlada de farmacos de retencion gastrica.
HK1046244B (zh) 控制釋放與掩蔽味道的口服藥物組合物
MXPA04004791A (es) Polvo micronizado para la formacion de peliculas que comprenden una sustancia activa.
UA86413C2 (ru) Сахарное покрытие и твердая дозированая форма, которая его содержит
MY148867A (en) Gastric retention drug delivery system
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DE59903917D1 (de) Überzugs- und bindemittel für orale oder dermale arzneiformen
WO2005046745A3 (en) Method and device for controlled delivery of active substance
HK1074581A1 (en) Pharmaceutical tablet
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
PL376099A1 (en) Modified release pharmaceutical composition
MXPA05011446A (es) Tableta con liberacion retardada con geometria de nucleo definida.
MX2009013497A (es) Metodo para mejorar el crecimiento de una planta.
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
HUP0203813A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use
IL164221A0 (en) Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
WO2006049564A8 (en) New modified release pellet formulations for proton pump inhibitors
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative

Legal Events

Date Code Title Description
FG Grant or registration